Skip to main content

Chi-Med Approved to Market Surufatinib for Neuroendocrine Tumors

Hutchison China MediTech (Chi-Med) announced surufatinib was approved in China to treat non-pancreatic neuroendocrine tumors (NETs). Surufatinib has a dual mechanism, inhibiting angiogenesis and promoting tumor-associated macrophages. Chi-Med expects it will have synergistic effects when paired with other immunotherapies. Surufatinib, which will be marketed in China under the brand name Sulanda ®, is the second Chi-Med product to reach commercialization. The first was fruquintinib in 2018, marketed as Elunate ® , a treatment for colorectal cancer. More details.... Stock Symbols: (NSDQ/AIM: HCM) Share this with colleagues: // //
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.